Drug company's meetings with FDA raise suspicions, investigation sought

The acting head of the Food and Drug Administration urged for a government investigation into unusual contacts between members of her agency and the maker of a controversial new drug for Alzheimer's disease Friday.

Dr. Janet Woodcock, acting commissioner of the FDA, tweeted that due to "Ongoing interest and questions" she has asked the Office of the Inspector General, U.S. Department of Health and Human Services for an independent investigation into the "Interactions between representatives of Biogen and FDA" during the approval process for Aduhelm, an Alzheimer's drug.

Biogen's drug Aduhelm was approved by the FDA in June, against the expertise of their own statisticians who said there wasn't enough evidence the expensive drug was effective.

The collaboration between Biogen and the FDA's drug review staff was unusually close, with an undocumented meeting between a top Biogen executive and the FDA's lead reviewer for Alzheimer's drugs taking place in May 2019, according to STAT, a health news site.

Is the FDA engaged in nefarious collaboration with drug makers?

100%. 0%. The meeting came in the aftermath of Biogen stopping two studies showing that the drug failed to slow the disease as expected.

Biogen and the FDA then went over all the data together and ended up approving the drug based on its ability to reduce the buildup of beta-amyloid brain plaques in the brain, which are considered to be a component of Alzheimer's, the AP reported.

https://www.wnd.com/2021/07/drug-companys-meetings-fda-raise-suspicions-investigation-sought/